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Internationally there are >10 million new cancer cases and >7
million cancer related death reported each year making cancer
research a top priority. As per WHO report 1997 cancer contin-
ues to be a major health problem in urban areas and during the
next 25 years or so cancer alone will contribute 6.3 million an-
nual deaths (Doreswamy and Darshan, 1999). Cancer is a dis-
ease of cells characterized by reduction or loss of effectiveness
in normal cellular control mechanism which regulates multipli-
cation. Carcinogenesis is a multi-step process as was ﬁrst de-
scribed in 1965 by Leslie Foulds, who deduced that there
were multiple pathological processes of cancer induction and
tumor progression for many human epithelial cancers.
Cancerogenesis is of a three stage process. The ﬁrst stage is
initiation which involves in the mutation by physical, chemical
or viral exposure and occurs rapidly with high frequency. The
second stage is tumor promotion, a low frequency event that
requires sustained chronic exposure to tumor promoters, such
as growth factors, hormones or ultraviolet radiation. The third
stage is tumor progression in which tumor becomes malignant.
Many cancer cells have defects in their progression through the
cell cycle or their regulation of cell death. In particular, the dis-
tinct feature of tumors is lack of regulation of the cell cycle,
resulting in uncontrolled proliferation. Although the goal of
cell division is for each daughter cell to inherit a copy of each
intact chromosome, defects in this process can lead to aneu-
ploidy, genetic instability and ultimately, metastatic tumori-
genesis. A list of various chemotherapeutic drugs is
summarized in Table 1 (Goodman and Gilman’s, 2001).
In the past, due to poor therapeutic response and high inci-
dence of adverse reactions, chemotherapy was considered as a
last resort, after more successful treatments like surgery and
radiotherapy had failed. However, even with recent advances,
the treatment of cancer continues to be one of the greatest chal-
lenges in medicine, as many forms of human cancers still resist
effective chemotherapy. A major limitation in cancer therapy is
inadequate selectivity of most anti-cancer drugs (Prasanna
et al., 2003). COX-2 (also known as prostaglandin H syn-
thase-1) is upregulated in response to inﬂammatory cytokines,
growth factors and tumor promoters (Matthew et al., 2003).
2. Various chronic inﬂammatory conditions that predispose to
cancer
Various chronic inﬂammatory conditions predispose to the
neoplastic transformation. Tumors are mostly of epithelial cellorigin (carcinomas). Various cancerous disease associated with
inﬂammatory conditions such as colon carcinoma associated
with inﬂammatory bowel disease (chronic ulcerative colitis
and Crohn’s disease), esophageal adenocarcinoma associated
with reﬂux esophagitis (Barrett’s esophagus), hepatitis predis-
posing to liver cancer, schistosomiasis causing an increased
risk of bladder and colon carcinomas, and chronic Helicobac-
ter infection leading to cancer of the stomach. Some increase in
the incidence of lymphoma is also seen, particularly mucosa-
associated lymphoid tissue (MALT) lymphoma.
2.1. Chronic inﬂammatory model that leads to progression of
tumors
Different animal models demonstrate experimentally that
chronic inﬂammation predisposes to the development of vari-
ous forms of cancer (Vainio and Boffetta, 1994; Thieblemont
et al., 1995). Marmosets have a high incidence of spontaneous
colitis and a high incidence of colon cancer as well (Ekbom
et al., 1990). For example, the cancer status of parents and
grandparents was compared for 48 animals with colon cancer
and 58 for controls, all with histological conﬁrmation of ulcer-
ative colitis. Multivariate odds ratios (OR) were calculated
using logistic regression. A parental history of colon cancer
was associated with risk of colon cancer (multivariate odds ra-
tio, 2.7; 95% conﬁdence interval, 1.1–6.3). Risk also increased
as an animal’s total number of family members with colon can-
cer increased (multivariate odds ratio, 1.7 for each increase in
the total number of family members with cancer; 95% conﬁ-
dence interval, 1.1–2.8). These results suggested that cotton-
top tamarins with ulcerative colitis have a signiﬁcant increased
risk for developing colon cancer if they have a family history of
colon cancer (Elizabeth et al., 1998). Skin cancer is induced by
administration of carcinogens such as dimethylbenzanthracine
(DMBA) followed by repeated administration of tumor pro-
moters such as phorbol myristate acetate (PMA) or benzoyl
peroxide, which induces inﬂammation and the production of
various inﬂammatory mediators (Boone et al., 1992). Plasma-
cytoma can be induced with high frequency in BALB/c mice by
the intra peritoneal introduction of mineral oils (e.g. pristane)
and implantation of plastic Lucite discs (Vogelstein and Kin-
zler, 1993). These types of plasmacytoma have showed that
the tumors developed in the peritoneal inﬂammatory tissue.
In some cases, there is strong evidence suggesting a genetic
basis for the susceptibility to tumor development. For exam-
ple, in the mouse plasmacytoma model, BALB/c mice were un-
iquely susceptible to developing plasma cell tumors in response
Table 1 List of chemoprotective agents.
Class Type of agent Drugs Disease Structure
Alkylating agents Nitrogen mustard Mechlorethamine Hodgkin’s disease, non-Hodgkin’s
lymphomas
N
Cl
Cl
2-chloro-N-(2-chloroethyl)-N-methyl-ethanamine
Cyclophosphamide,
Ifosfamide
Acute and chronic lymphocytic
leukemia; Hodgkin’s disease, non-
Hodgkin’s lymphomas; multiple
myeloma
O NH
P
O N
Cl
Cl
N,N-bis(2-chloroethyl)-1,3,2-
oxazaphosphinan-2-amine-2-oxide
N
P
O
H
N
Cl
Cl
O
N-3-bis(2-chloroethyl)-1,3,2-
oxazaphosphinan-2-amide-2-oxide
Melphalan Multiple myeloma; breast, ovarian
cancer
H2N O
OHN
Cl
Cl
4-[bis(chloroethyl)amino]phenylalanine
Chlorambucil Chronic lymphocytic leukemia,
primary macroglobulinemia,
Hodgkin’s disease, non-Hodgkin’s
lymphomas
O
HO
N
Cl
Cl
4-[bis(2-chlorethyl)amino]benzenebutanoic acid
Ethylenimines and
methylmelamines
Hexamethylmelamine Ovarian cancer
N
N
NN
N
N
N2,N2,N4,N4,N6,N6-hexamethyl-1 ,3,5-triazine-2,4,6-triamine
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Table 1 continued
Class Type of agent Drugs Disease Structure
Thiotepa Bladder, breast, ovarian cancer
PS
N
N
N
1,1',1''-phosphorothioyltriaziridine
Alkyl sulfonates Busulfan Chronic granulocytic leukemia
SO O
OS
O
O
O
Butane-1,4-diyl dimethanesulfonate
Nitrosoureas Carmustine Hodgkin’s disease, non-Hodgkin’s
lymphomas; primary brain tumors,
multiple myeloma, malignant
melanoma
N
O
H
N
N
O
Cl
Cl
N,N'-bis(2-chloroethyl)-N-nitroso-urea
Lomustine Hodgkin’s disease
N
O
HN
NO
Cl
N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea
Triazenes Dacarbazine Malignant melanoma, Hodgkin’s
disease
N
NH
OH2N
N
N
N
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
4
N
.
K
u
m
a
r
et
a
l.
Antimetabolites Folate antagonist Methotrexate Acute lymphocytic leukemia;
choriocarcinoma; breast, head and
lung cancer
O
OH
O
HO
HN
O
N
N
N
N
N
NH2
H2N
(2S)-2-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}
benzoyl)amino]pentanedioic acid
Pyrimidine analogs Fluorouracil Breast, colon, stomach, pancreas,
ovarian, head and neck, urinary
bladder cancer
N
H
NH
OO
F
5-fluoro-1H-pyrimidine-2,4-dione
Cytarabine Acute granulocytic and lymphocytic
leukemia
N
N
O
O
HO
HO
OH
NH2
4-amino-1-[(2R,3S,4R,5R)-3,4-dihydroxy-5-
(hydroxymethyl)oxolan-2-yl] pyrimidin-2-one
Purine analogs Mercaptopurine Acute granulocytic and lymphocytic
leukemia
NH
N
N
H
N
S
3,7-dihydropurine-6-thione
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Table 1 (continued)
Class Type of agent Drugs Disease Structure
Natural products Vinca alkaloids Vinblastine Hodgkin’s disease, non-Hodgkin’s
lymphomas, breast and testis cancer
N
N
H
OH
O
O
O O
N
N
H
O
O
OH
H
O
Dimethyl (2ß,3ß,4ß,5a,12ß,19a)- 15-[(5S,9S)- 5- ethyl- 5-hydroxy- 9-(methoxycarbonyl)-1,4,5,6,7,8,
9,10-octahydro- 2H- 3,7-methanoazacycloundecino[ 5,4-b]indol- 9-yl] - 3-hydroxy- 16-methoxy- 1-
methyl- 6,7-didehydroaspidospermidine- 3,4-dicarboxylate
Vincristine Acute lymphocytic leukemia,
neuroblastoma, Wilm’s tumor
N
N
H
OH
O
O
O O
N
N
H
O
O
OH
H
O O
H
Methyl (1R,9R,10S,11R,12R,19R)- 11-(acetyloxy)-12-ethyl- 4-[(13S,15S,17S)-
17-ethyl- 17-hydroxy- 13-(methoxycarbonyl) - 1,11-diazatetracyclo[13.3.1.04,
12.05,10]nonadeca- 4(12),5,7,9-tetraen- 13-yl] - 8-formyl- 10-hydroxy- 5-
methoxy- 8,16-diazapentacyclo[10.6.1.01,9.02,7. 016,19]nonadeca- 2,4,6,
13-tetraene- 10-carboxylate
6
N
.
K
u
m
a
r
et
a
l.
Taxanes Paclitaxel, Docetaxel Ovarian, breast, lung, head and neck,
urinary bladder cancer
O NH
O
O
OH
O OH
O
O
O
HO O
H
O
O O
(2a,4a,5ß,7ß,10ß,13a)-4,10-bis(acetyloxy)-13-{[(2R,3S)-
3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy}-1,
7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
O NH
O
O
OH
HO OH
O
O
HO O
H
O
O O
H
1,7ß,10ß-trihydroxy-9-oxo-5ß,20-epoxytax-11-ene-2a,
4,13a-triyl 4-acetate 2-benzoate-13-{(2R,3S)-3-[(tert-
butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}
(continued on next page)
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Table 1 (continued)
Class Type of agent Drugs Disease Structure
Epipodophylotoxins Etoposide, Teniposide Testis, small-cell lung, breast cancer;
Hodgkin’s disease, non-Hodgkin’s
lymphomas, acute granulocytic
leukemia
O
OO
H
HO
O
HO
H
O
O
O
H
H
O
OH
O
O
4'-demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene
-beta-D-gluco-pyranoside], 4'-(dihydrogen phosphate)
N
N
O
O O
HO O
N
O
N
(S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano
[3’,4’:6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4’bipiperidine]-1’-carboxylate
8
N
.
K
u
m
a
r
et
a
l.
Camptothecins Topotecan, Irinotecan Ovarian cancer, small-cell lung
cancer, colon cancer
O
N
O
NH2
HN O O NH
HN
HN
O
O
N
N
ON
O
O
O O
O
N
NO
O
N
O
O
2-amino-N,N'- bis[(6S,9R,10S,13R,18aS)-6,13-diisopropyl- 2,5,9-trimethyl- 1,4,7,11,
14-pentaoxohexadecahydro- 1H-pyrrolo[2,1-i] [1,4,7,10,13] oxatetraazacyclohexadecin
- 10-yl]- 4,6-dimethyl- 3-oxo- 3H-phenoxazine- 1,9-dicarboxamide
N
N
O
O O
HO O
N
O
N
(S)-4,11-diethyl-3,4,12,14-tetra hydro-4-hydroxy-3,14-dioxo-1H-pyrano
[3’,4’:6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4’bipiperidine]-1’-carboxylate
(continued on next page)
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Table 1 (continued)
Class Type of agent Drugs Disease Structure
Antibiotics Dactinomycin Choriocarcinoma, Wilm’ tumor,
Kaposi’s sarcoma
O
N
O
NH2
HN O O NH
HN
HN
O
O
N
N
ON
O
O
O O
O
N
NO
O
N
O
O
2-amino-N,N'- bis[(6S,9R,10S,13R,18aS)-6,13-diisopropyl- 2,5,9-trimethyl- 1,4,7,11,
14-pentaoxohexadecahydro- 1H-pyrrolo[2,1-i] [1,4,7,10,13] oxatetraazacyclohexadecin
- 10-yl]- 4,6-dimethyl- 3-oxo- 3H-phenoxazine- 1,9-dicarboxamide
Daunorubicin Acute granulocytic and lymphocytic
leukemia
O
OO
H3C
OH
OH
CH3
O
OH
O O
CH3
CH3
CH3
(8S,10S)-8-acetyl-10-[(2S,4S,5S,6S)-4-amino-5-hydroxy-
6-methyl-oxan-2-yl]oxy-6,8,11-trihydroxy-1-methoxy-
9,10-dihydro-7H-tetracene-5,12-dione
1
0
N
.
K
u
m
a
r
et
a
l.
Doxorubicin Soft-tissue, osteogenic, Hodgkin’s
disease, non-Hodgkin’s lymphomas;
breast, thyroid, lung cancer
O
OH
OH
O
OH
O O
NH2
OH
H
OH
(8S,10S)-10-(4- ino-5-hydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-6,8,
11-trihydroxy-8 -hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,
12-dione
Bleomycin Testis, skin, lung, head and neck,
urinary bladder cancer
O
O
O
OH
OH
O
HO
OH
H
NH2
O
OH
HO
N NH
HN
O
HN
ON N
O
NH2
HN
H2N O
H2N
H2N
N
H
OH
O
HO
O
H
N
N
S
S
N
H
NS
(3-{[(2'-{(5S,8S,9S R,13S)-15-{6-amino-2- [(1S)-3-amino-1-{[(2S)-2,3-diamino-3 oxopropyl] 
amino}-3-oxoprop -5-methylpyrimidin-4-yl}-13-[{[(2R,3S,4S,5S,6S)-3-{[(2R,3S,4S,5R,6R)-4-
(carbamoyloxy)-3, ihydroxy-6- (hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy} -4,5-dihydroxy-6-
(hydroxymethyl)te ydro-2H-pyran-2-yl]oxy} (1H-imidazol-5-yl)methyl]-9-hydroxy-5-[(1R)-1-
hydroxyethyl]-8,10 methyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazapentadec-1-yl}-2,4'-bi-1,3- thiazol-4-
yl)carbonyl]amino opyl)(dimethyl)sulfonium
(continued on next page)
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Table 1 (continued)
Class Type of agent Drugs Disease Structure
Mitomycin Testis, skin, lung, head and neck and
genitourinary tract cancer
H2N
O
O
N
HN
O
O
O
NH2
[6-Amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-
octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate
Miscellaneous Platinum
coordination
complexes
Cisplatin, Carboplatin Testis, ovary, bladder, head and neck,
lung, thyroid, osteogenic sarcoma
Pt
Cl NH3
Cl NH3
(SP-4-2)-diamminedichloridoplatinum
cis-diammine(cyclobutane-1,1-dicarboxylate-O,O')platinum(II)
Pt
O
O
NH3
NH3
Substituted urea Hydroxyurea Chronic granulocytic leukemia
N
H
O
H2N
OH
Hydroxyurea
1
2
N
.
K
u
m
a
r
et
a
l.
Methylhydrazine
derivatives
Procarbazine Hodgkin’s disease
O
H
NNH
HN
N-isopropyl-4-[(2-methylhydrazino)methyl]benzamide
Tyrosine kinase
inhibitors
Imatinib Chronic myelocytic leukemia
O
NH
NH
N
N
N
NN
4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-
yl]amino}phenyl)benzamide
Hormones and
antagonist
Adrenocorticosteroids Prednisone Acute and chronic lymphocytic
leukemia, Hodgkin’s disease,
non-Hodgkin’s lymphomas
H
OH
O
O
O
H H
OH
(8S,9S,10R,13S,14S,17R)-7,8,13,15,16,17-hexahydro-17-hydroxy-17-(2-hydroxyacetyl)-
10,13-dimethyl-6H-cyclopenta[a]phenanthrene-3,11(9H,10H,12H,14H)-dione
(continued on next page)
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Table 1 (continued)
Class Type of agent Drugs Disease Structure
Progestins Hydroxyprogesterone caproate,
Medroxyprogesterone acetate,
Megestrol acetate
Endometrium, breast cancer
O
O
H H
OO
O
(8R,9S,10R,13R,14S,17R)-13-acetyl-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-8,10-dimethyl-
3,11-dioxo-1H-cyclopenta[a]phenanthren-17-yl hexanoate
O
O
H H
O
O
O
(6S,8S,9S,10R,14R,17R)-17-acetyl-2,3,6,7,8,9,10,11,12,13,14,15,16,17-
tetradecahydro-6,8,10-trimethyl-3,11-dioxo-1H-cyclopenta[a]phenanthren-17-yl 
acetate
O
O
H H
HO
O
(8S,9S,10R,13S,14S,17R)-17-acetyl-1,7,8,10,13,15,16,17-octahydro-17-hydroxy-
6,8,10,13-tetramethyl-2H-cyclopenta[a]phenanthrene-3,11(6H,9H,12H,14H)-dione
1
4
N
.
K
u
m
a
r
et
a
l.
Estrogens Diethylstilbestrol Breast, prostate cancer
OH
HO
4,4'-(3E)-hex-3-ene-3,4-diyldiphenol
Antiestrogen Tamoxifen Breast cancer
N
O
(Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
Androgens Testosterone propionate Breast cancer
O
O
H H
OH
(8S,9S,10R,13S,14S,17S)-1,7,8,10,13,15,16,17-octahydro-17-hydroxy-8,10,13-
trimethyl-2H-cyclopenta[a]phenanthrene-3,11(6H,9H,12H,14H)-dione
(continued on next page)
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Similarly, SENCAR mice were uniquely susceptible to devel-
oping skin tumors in response to DMBA and PMA. On the
basis of these results it showed that critical genes and factors
contribute to tumor development. Individuals with chronic
inﬂammatory conditions and carcinogen exposure (e.g. smok-
ers) developed cancer while others do not.
The different progenitors of the inﬂammation are known;
which includes chronic bacterial and parasitic infections,
chemical irritants and non-digestible particles. Studies showed
that any parasitic infection that persists or recurs over many
years can predispose to cancer.
2.1.1. Progenitors of inﬂammation due to bacterial infections
lead to cancer
The strongest association between chronic bacterial infection
and the development of cancer involved the organism Helico-
bacter pylori, which is associated with at least a twofold-in-
creased risk of adenocarcinoma of the stomach (Slaga et al.,
1978 and Potter, 1999). In addition, H. pylori infection also in-
creased the incidence of MALT lymphoma (Correa, 1995). H.
pylori infection is the major risk factor in gastric cancer and
the eradication of H. pylori can reverse many biochemicals, ge-
netic and epigenetic changes which induce in the stomach lead-
ing to the development of gastric cancer (GC). Helicobacter
infection in humans is always accompanied by mucosal inﬂam-
mation (gastritis) with an inﬂux of lymphocytes, plasma cells,
and neutrophils. The International Agency for Research on
Cancer (IARC) in its meeting in 1994 in Lyon, France, con-
cluded that there is sufﬁcient evidence to classify H. pylori as
‘‘Group 1 = Deﬁnite’’ human carcinogen (IARC Monograph,
1994). The strongest evidence came from control studies based
on serological evidence of the H. pylori infection. Overall con-
clusion of six meta-analyses was that H. pylori infection was
associated with approximately a twofold-increased risk of
developing a GC range of pooled odds ratios of 1.92–2.56,
all with signiﬁcant 95% conﬁdence intervals. The strong asso-
ciation between H. pylori infection and GC has been obtained
in a widely publicized prospective study involving 1526 Japa-
nese patients with duodenal ulcers, gastric ulcers, gastric
hyperplasia or nonulcer dyspepsia at entry. After a follow-up
period of 7–8 years, GC was detected in 2.9% of H. pylori po-
sitive patients and not in any participant without H. pylori
infection. Huang et al. identiﬁed 16 qualiﬁed studies with
2284 cases and 2770 controls. H. pylori seropositivity signiﬁ-
cantly increased the risk of GC by 2.28 folds. The same study
found that an association between H. pylori infection and GC
was equally strong for intestinal and diffuse cancer [odds ratio
2.49 (95% CI, 1.41–4.43)] with a 2.58 [(95% CI, 1.47–4.53)]
(Uemura et al., 2001; Huang et al., 2003; Wong et al., 2004;
Forman and Pisani, 2008; Siman et al., 2007) Eradication of
Helicobacter pylori infection with antibiotics may also elimi-
nate the excess risk for cancer, but this has not yet been
established.
2.1.2. Progenitors of inﬂammation due to parasitic infections
lead to cancer
Several parasitic infections are well known to increase the risk
of cancer. Schistosomiasis was prevalent primarily in the third
world countries and is difﬁcult to treat and it causes due to
contaminated water supplied (Parsonnet, 1995). Chronic schis-
tosomiasis induces cystitis, ﬁbrosis and increases the incidenceof carcinoma of the bladder, liver and rectum and follicular
lymphoma of the spleen, with different strains of the parasites
infecting speciﬁc organs and causes various cancers (Konturek
et al., 1999). Liver ﬂukes (Opisthorchis and Clonarchis), intro-
duced by eating raw ﬁsh, infect the bile duct and lead to
chronic cholangitis associated with an increased incidence of
cholangiocarcinoma (Tavani et al., 2000). Chronic infection
and inﬂammatory diseases may also contribute to the develop-
ment of Hodgkin’s disease and non-Hodgkin’s lymphoma (Co-
pie-Bergman et al., 1997).2.1.3. Progenitors of inﬂammation due to viral infections lead to
cancer
Many different viruses cause an increased incidence of cancer.
Chronic inﬂammation associated with the hepatitis B and C
viruses, which lead to chronic active hepatitis and hepatocellu-
lar carcinoma, Epstein–Barr virus (EBV) is associated with B-
cell non-Hodgkin’s lymphoma (Bornstein et al., 1995). Other
viral infections can also increase the incidence of cancer, but
the role of inﬂammatory mediators is less clear. For example,
the human papillomavirus, herpes simplex virus 2, and cyto-
megalovirus have been implicated in cervical and other carci-
nomas (Tung et al., 2001). Among RNA retroviruses, the
human immunodeﬁciency virus (HIV) helps in the develop-
ment of non-Hodgkin’s lymphoma, squamous cell carcinomas,
and Kaposi’s sarcoma while the human T-cell lymphoma virus
causes adult T-cell leukemia (Seitz et al., 1998).
Unlike the other parasitic infections described here, viruses
implicated in inducing neoplasia directly infect the cells that
ultimately undergo neoplastic transformation. Hence, it is dif-
ﬁcult to determine whether these agents act by causing a
chronic inﬂammatory condition, by directly transforming the
cells that they infect, or both. Most of these viruses induce
chronic increased proliferation of the infected cells, thus pre-
disposing to neoplastic transformation. For example, EBV
causes sustained proliferation of peripheral B-lymphocytes,
but when coupled with a secondary mutation can result in a
malignant transformation, such as occurs with the chromo-
somal translocations that activate the c-myc oncogene in Bur-
kitt’s lymphoma. The hepatitis viruses are thought to give rise
to hepatocellular carcinoma by causing liver damage and
regeneration together with the generation of secondary inﬂam-
matory mediators (Steenland and Stayner, 1997).3. Non-infectious causes of chronic inﬂammation lead to cancer
Various non-infectious agents also cause chronic inﬂammation
associated with an increased risk of cancer. For example,
esophageal reﬂux causes chronic exposure of the esophageal
epidermis to irritation by gastric acids. This leads to reﬂux
esophagitis, or Barrett’s esophagus, and subsequent develop-
ment of esophageal carcinoma (Hanahan and Weinberg,
2000). Excess fecal bile acids in patients with primary scleros-
ing cholangitis and ulcerative colitis are associated with an in-
creased risk of colorectal carcinoma. A recent publication
demonstrated that ursodiol, a drug that reduces the colonic
levels of deoxycholate and other bile acids (used to treat cho-
langitis), signiﬁcantly reduces the incidence of neoplasia (Hen-
nings et al., 1993). Chronic irritation of the liver by alcohol
causes cirrhosis and hepatocellular carcinoma (Jackson et al.,
1997).
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lead to chronic inﬂammation in the lung because of the inabil-
ity of the immune system to remove the substances. Such ster-
ile inﬂammations increase the incidence of epithelial cancers
including mesothelioma and lung carcinoma (Baron and San-
dler, 2000). Environmental carcinogen exposure is a requisite
for the development of mostly all lung cancers such as asbestos
exposure interacts synergistically with tobacco smoke to in-
duce lung cancer. Previous studies have suggested that asbestos
was associated with the presence of a k-ras mutation in adeno-
carcinoma of the lung. k-ras mutation is strongly associated
with adenocarcinoma. There were 84 male patients with avail-
able questionnaire-derived work history data and parafﬁn-
embedded tumor tissue for determination of k-ras mutation
status. Chest radiographic evaluation was done for all of the
patients who reported occupational exposure to asbestos.
The prevalence of k-rasmutation was higher among those with
a history of occupational asbestos exposure (crude odds ratio,
4.8; 95% conﬁdence interval, 1.5–15.4) compared to those
without asbestos exposure, and this association remained after
adjustment for age and pack-years smoked (adjusted odds ra-
tio, 6.9; 95% conﬁdence interval, 1.7–28.6). These data suggest
that asbestos exposure increases the likelihood of mutation at
k-ras codon 12 and that this process occurs independently of
the induction of interstitial ﬁbrosis (Nelson et al., 1999). Ciga-
rette smoke is a complex pro-neoplastic agent that may act, in
part, by inducing a chronic inﬂammatory condition. Smoking
not only causes chronic bronchitis, but also delivers an array
of genotoxic carcinogens (e.g. nitrosamines, peroxides) into
the lungs. Deﬁnitive evidence that chronic inﬂammation pre-
disposes to cancer requires identiﬁcation of the causative
inﬂammatory mediators as well as the agents that prevent neo-
plastic transformation through inhibition of the inﬂammatory
process. The remainder of this review will focus on the mech-
anisms whereby inﬂammatory mediators promote neoplastic
transformation.4. Prostaglandins a mediator responsible for development of
cancer
Different evidence from human and animal studies suggests
that prostaglandins contribute to the development of cancer
(Herschman 1996; Giovannucci et al., 1995). Prostaglandins
such as prostaglandin E2 (PGE2) are lipid mediators of the
inﬂammatory immune response and are derived from oxidative
metabolism of arachidonic acid. These lipids are synthesized in
large quantities by inﬂammatory cells in response to both
acute and chronic inﬂammatory stimuli. Two different cyclo-
oxygenase (COX) enzymes catalyze the rate-limiting ﬁrst step
in prostaglandin synthesis (Labayle et al., 1991). COX-2 is ex-
pressed during inﬂammation. Its primary site of synthesis is
inﬂammatory monocytes and macrophages, but it is also ex-
pressed in noninﬂammatory cells, such as ﬁbroblasts, epithelial
cells, and endothelial cells. Bacterial cell products and inﬂam-
matory cytokines induce in vitro expression of COX-2. Exper-
imental induction of COX-2 in animal models is accomplished
with agents that induce chronic inﬂammation such as adminis-
tration of azoxymethane to rats. COX-1 is a constitutive en-
zyme expressed in most cell types and is associated with
regulation of housekeeping functions such as gastric acid
secretion.4.1. Tumorigenesis promotes by prostaglandins
Many different mechanisms have been proposed to explain the
mechanisms of tumorigenesis by prostaglandins (Upulescu,
1996). Prostaglandins can stimulate cell proliferation, induce
synthesis of cytokines such as IL-6 that serve as tumor growth
factors, synthesis of prostaglandins is coupled with formation
of DNA-reactive by-products with mutagenic potential; e.g.
formation of malondialdehyde (MDA) from prostaglandin
G2, and it also can induce angiogenesis, which is required for
growth and metastasis of tumors. It has been suggested that
these drugs may not be acting entirely through the inhibition
of PGE2 synthesis because the addition of exogenous PGE2
fails to overcome the inhibitory effect of the NSAIDs (Sakata
et al., 1986). However, the concentrations of NSAIDs required
to inhibit prostaglandin-independent angiogenesis in vitro are
quite high (e.g. 250–500 lM of indomethacin) and are unlikely
to be achieved in vivo. In contrast, inhibition of prostaglandin
synthesis byNSAIDs occurs at concentrations that are achieved
in vivo (e.g. 1 lMor less for indomethacin) (Carter et al., 1989).
In addition to serving as pro-inﬂammatory mediators, pros-
taglandins are also immunosuppressive. By inhibiting the func-
tions of T-cells and macrophages, they may decrease immune
surveillance and thereby allow nascent tumor cells to escape
detection by the immune system. Prostaglandins may inhibit
apoptosis of tumor cells by increasing expression of the anti-
apoptotic oncogene bcl-2 or by removing arachidonic acid,
which is thought to be pro-apoptotic. It also stimulates cell
signaling through peroxisome-proliferator-activated receptor
delta (PPAR-d), a transcription factor that regulates prolifer-
ation-associated genes.
4.2. Cytokines
Inﬂammatory cells secrete a large number of cytokines and
chemokines that can promote the outgrowth of neoplastic
cells. These factors are produced in response to pro-inﬂamma-
tory stimuli such as bacterial lipopolysaccharide. Neoplastic
cells have a reduced need for normal metabolic factors, but
they often require the presence of speciﬁc cytokines in order
to proliferate, at least in the early stages of tumor develop-
ment. Many tumor cells developing in chronically inﬂamed tis-
sue cultivate a growth advantage by acquiring the ability to
proliferate in response to cytokines. They may express growth
factor receptors abnormally or alter their response to the fac-
tors by undergoing cell division instead of differentiation.
Examples of tumor cell cytokine dependence in human dis-
ease are the growth dependence of AIDS- and EBV-associated
B-cell lymphomas, B-cell leukemia, and multiple myeloma on
the inﬂammatory cytokines IL-6 and IL-15 and the depen-
dence of malignant mesothelioma on platelet-derived growth
factor (Reddy et al., 1987; Yamamoto et al., 1992). Mono-
cytes, macrophages, and T-cells are major sources of cytokines
that promote outgrowth of preneoplastic and malignant cells,
in addition to autocrine growth factor production by the tu-
mor cells themselves.
4.3. Tumor progression mechanisms
Cytokines can contribute to tumor progression by mechanisms
other than direct stimulation of cell growth. One such mecha-
nism involves inducing the production of reactive oxygen and
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enhance the formation of reactive oxygen intermediates by
neutrophils and other cells. IL-1-beta, TNF-alpha, and inter-
feron (IFN)-gamma stimulate expression of inducible nitric
oxide synthase and the formation of nitric oxide in cholangio-
carcinoma. This process has been shown to cause DNA dam-
age and inhibit DNA repair in tumor cells. IL-8 can promote
tumorigenesis through two different mechanisms. One involves
induction of angiogenesis, possibly through the synthesis of
matrix metalloproteinases. In addition, IL-8 recruits inﬂam-
matory neutrophils to the site of inﬂammation and may there-
by increase formation of reactive oxygen and nitrogen
intermediates. Some cytokines may also promote tumorigene-
sis by inducing immunosuppression, as is suggested for trans-
forming growth factor-beta.5. NSAIDs and novel agents
Chronic intake of NSAIDs may reduce carcinogenesis by inhib-
iting production of prostaglandins, cytokines, and angiogenic
factors. Note that NSAIDs do not eliminate inﬂammation
but rather act by reducing the production of selected inﬂamma-
tory factors. Hence, unlike steroids, they do not suppress ele-
ments of the immune response that are necessary for tumor
depletion such as T-cells, NK cells, and macrophages. COX-2
selective inhibitors may provide a safer method for chemopre-
vention than older NSAIDs such as aspirin and indomethacin,
which also inhibit COX-1 activity and cause gastric lesions.
NSAIDs exert analgesic, antipyretic, and anti-inﬂamma-
tory effects through the inhibition of COX-catalyzed biosyn-
thesis of prostaglandin’s (Nakadate et al., 1982). Moreover,
the ability of these NSAIDs drugs to prevent cancer is thought
to be due, in part, to COX inhibition. Currently, there are two
known isoforms of COX, both of which catalyze the metabo-
lism of arachidonic acid to prostaglandin H2, a precursor to
prostaglandins (Earashi et al., 1995). The COX-1 isoform is
constitutively expressed and produces the prostaglandins
important for normal physiological function. COX-2 can be
induced by cytokines, growth factors, and tumor promoters
and produces prostaglandins at sites of inﬂammation (Parrett
et al., 1997). In carcinogenesis, over expression of COX is
thought to deregulate arachidonic acid metabolism and lead
to elevated prostaglandin production (Buckmann et al.,
1998). The incidence of COX-2 protein expression gradually
increases with the development of esophageal lesions, from
75% in metaplasia, to 83% in low grade dysplasia and up to
100% in high-grade dysplasia (Morris et al., 2001). Increased
prostaglandin (PG) levels have been observed in human and
animal tumors compared with surrounding normal tissue
and are thought to contribute to colon carcinogenesis by inﬂu-
encing cell proliferation, tumor promotion, immune response,
and metastasis (Marnett, 1992; Kraemer et al., 1996). In-
creased PG synthesis caused stimulation of cell proliferation
and contributed to the development of dysplasia in Barrett’s
epithelium (Zhang et al., 2001).
The role of arachidonic acid metabolites as modulators in
the multi-step process of carcinogenesis, particularly in tumor
promotion, has often been postulated with supportive evidence
from epidemiological and experimental studies. This notion is
strengthened by reports on a reduced mortality and a lower
incidence of human colon cancer following chronic consump-tion of non-steroidal anti-inﬂammatory drugs (NSAIDs), e.g.
acetylsalicylic acid (Puga et al., 1997). Sulindac and indometh-
acin suppress the number and size of colonic polyps in patients
with familial adenomatous polyposis (Vogel et al., 1998; Red-
dy et al., 1987). Moreover, inhibitors of cyclooxygenase and
lipoxygenase activities decrease the tumor promoting effects
of various structurally unrelated agents and inhibit the growth
of tumor cells in vivo and in vitro. The impact of arachidonic
metabolism on tumorigenesis is based on the following obser-
vations: (i) the levels of speciﬁc metabolites of arachidonic acid
and the expressions of cyclooxygenases and lipoxygenases are
enhanced in various human and rodent tumors and (ii) the
cyclooxygenase isoenzyme COX-2 is induced in normal tissues
by the treatment with tumor promoters, e.g. TCDD and TPA
(Levy, 1997). Interestingly, the induction of COX-2 has been
observed in pathological processes including tumor promo-
tion. Thus, in a quest for a more mechanistic risk assessment
pertaining to tumor promoters such as dioxin-like compounds,
the expression of cyclooxygenase activities may provide an
important link necessary for this goal (Rubio, 1984).
5.1. Chemoprotection by NSAIDS
A growing body of evidence suggests that anti-inﬂammatory
medications, such as aspirin, NSAIDs and more recently
COX-2 selective inhibitors, have a chemoprotective effect
against a variety of neoplasms (Rubio, 1986). Coogan et al.
found that regular NSAID use (at least 4 days a week for
>3 months) reduced the risk of GC in a hospital based control
study of 254 patients (OR 0.3; 95% CI, 0.1–0.6). The protec-
tive effect was more pronounced among those patients using
NSAIDs continually for >5 years (OR 0.2; 95% CI, 0.1–
0.7) than for those using NSAIDs for <5 years (OR 0.4;
95% CI, 0.1–0.9) (Coogan et al., 2000). In a large cohort study
of 635,031 subjects followed over 6 years, the American Can-
cer Society demonstrated that regular exposure to aspirin
(>16 times/month) exerted a protective effect against GC;
aspirin users were found to have approximately 50% the risk
of GC compared with nonusers (OR = 0.53; 95% CI, 0.34–
0.81) (Yamagata et al., 2002). A recent metanalysis by Abnet
et al. found a signiﬁcant reduction in the incidence of GC in
aspirin or non-aspirin NSAID users (OR 0.74; 95% CI,
0.64–0.87 and OR 0.79; 95% CI, 0.71–0.89, respectively) (Ab-
net et al., 2009). There is compelling epidemiological evidence
that the regular or occasional use of aspirin or other NSAIDs
drug is inversely related to the risk of cancer (Zimmermann
et al., 1999; Wilson et al., 1998). The reduction in the relative
risk varies between 50% and 90%. A large study conducted by
the American Cancer Society reported a 40% reduction in the
risk of cancer in individuals who used aspirin 16 or more time
per month compared with those who never used aspirin. In
addition a population based case-control study found that cur-
rent users of aspirin and other NSAIDs have an almost 50%
reduction in the risk of developing either adenocarcinoma or
squamous cell carcinoma. Beside the epidemiological evidence,
experimental and preclinical evidence suggest a possible pre-
ventive or therapeutic beneﬁt of aspirin or other NSAIDs in
cancer. For example, Li et al . reported that treatment with
aspirin resulted in signiﬁcant growth inhibition of 10 esopha-
geal cancer cell lines (Shamma et al., 2000). This growth inhi-
bition was time and dose dependent and was associated with
the induction with apoptosis. Also, Rubio previously showed
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and delayed the growth of chemically induced esophageal can-
cer in mice either when given in tandem with NMBA (a potent
esophageal carcinogen) or when its delivery was delayed to al-
low tumor development (Shirvani et al., 2000; Liu et al., 2001).
Taken together, the evidence suggests a potential role for aspi-
rin and other NSAIDs in the prevention, and possible treat-
ment, of esophageal cancer. The only well known function of
NSAIDs to date is their ability to suppress PG synthesis.
6. COX-2 contributes to cancer: as preclinical evidence
Evidence suggests that COX-2 may contribute to esophageal
carcinogenesis. Increased amount of COX-2 is commonly
found in adenocarcinoma as well as squamous cell carcinoma
of the esophagus (Nasser, 2004 and Eling et al., 1990). In addi-
tion, over expression of COX-2 has been observed in premalig-
nant condition of the esophagus, such as squamous dysplasia
and Barrett’s esophagus (Souza et al., 2000). Shirvani et al. re-
ported a progressive increase in COX-2 expression with
increasing histological severity from metaplasia to low-grade
and high-grade dysplasia (Li et al., 2001). Increased COX-2
expression has also been associated with decreased survival
in patient with esophageal adenocarcinoma. The Approve trial
included a randomized multicenter, placebo controlled, double
blind trial to investigate whether the chronic use of the coxibCell membrane phospholipids
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branched and 4-bromobenzyl derivative.(rofecoxib 25 mg daily) would reduce the adenoma recurrence
in 2586 patients with a history of colorectal adenomas. Ther-
apy with rofecoxib was associated with a signiﬁcant reduction
in adenoma number and size. An increase in rofecoxib associ-
ated cardiovascular adverse events beginning at 18 months was
also noted, which led to early study termination (Baron et al.,
2006). Similarly, Bertagnolli et al. in a ﬁve-year efﬁcacy and
safety analysis of the adenoma prevention with celecoxib trial
found an inhibitory effect of celecoxib in colorectal adenoma
formation but they reported an elevated risk for cardiovascu-
lar and thrombotic adverse events [6% (RR, 1.6; 95% CI,
1.0–2.5) and 7.5% (RR, 1.9; 95% CI, 1.2–3.1) in celecoxib
200 and 400 mg twice daily users, respectively, compared to
3.8% in placebo group (Bertagnolli et al., 2009). However,
the most direct evidence supporting a cause-and-effect connec-
tion between COX-2 over expression and carcinogenesis comes
from genetic studies. In a seminal study Oshima et al. reported
that knocking out the COX-2 gene signiﬁcantly reduced the
numbers of intestinal polyps in a mouse model of familial ade-
nomatous polyposis. In another study, forced expression of the
COX-2 gene in the mammary gland of transgenic mice led to
the development of mammary cancer (Langergren et al.,
1999). These studies provide the most direct evidence of a
cause-and-effect relationship between COX-2 and cancer
development.
6.1. Reactions catalyze by COX [Fig. 1]
6.1.1. Insertion of molecular oxygen into arachidonic acid.
6.1.2. Conversion to PGH2 by the peroxidase activity
(Hameeteman et al., 1989).
6.2. Possible mechanism of COX-2 induced carcinogenesis
The effects of COX-2 are attributed by several pathways that
are potentially involved in the initiation and progression of
cancer, including xenobiotics metabolism, apoptosis, angio-
genesis, inﬂammation and immune surveillance.
6.3. Modiﬁcation of known indomethacin to improve its
speciﬁcity for COX-2
The Merck Frosst ﬁrst reported improving the selectivity of
indomethacin for COX-2 by making the larger trichloroben-
zoyl analog (Fig. 2). Exchanging the carboxylic acid moiety
of indomethacin for a 4-bromophenyle thiazole group
(Fig. 3) afforded the highly selective COX-2 inhibitor. It isH
N
Br
H3CO
COOH
CH3
CH3
Enlarged beta 
branched butyric 
acid providing 
COX-2 activity
4-bromobenzyl derivatives
C
omethacin, (B) trichlorobenzoyl analog and (C) enlarged beta
N
CH3
N
S
Br
H3CO
O
Cl
Figure 3 Exchanging with the carboxylic acid moiety of indo-
methacin with a 4-bromophenyle thiazole group.
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Figure 4 1-Benzoylindole, lacking a side chain at C-3 of the
indole nucleus, bind to the active site in COX-2, but in a cell based
assay inhibited prostaglandin formation by COX-2.
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chain at C-3 of the indole nucleus, bind to the active site in
COX-2, but in a cell based assay inhibited prostaglandin for-
mation by COX-2 (Kunkel et al., 1986).
6.4. Future direction
The substantial body of experimental and preclinical work re-
views shows that a link exists between COX-2 and tumor
development or progression. However, the role of COX-2
inhibitor in the prevention or treatment of human tumors re-
mains unsubstantiated. Numerous studies are currently in pro-
gress to evaluate both the safety and efﬁcacy of COX-2
inhibitor given either as a chemo preventive agent in patients
at a high risk for tumor development or in combination with
the standard cytotoxic agent to treat existing malignancies.The present study may lead to discovery of new or better
anti-cancer agents (Tsujii et al., 1998).7. Conclusion
This review will summarize the clinical association between
chronic inﬂammation and cancer and will describe the inﬂam-
matory factors and pathways that are thought to be pro-neo-
plastic agents. Emphasis will be placed on examining the role
of the reactive oxygen species, nitrogen intermediates, cyto-
kines and prostaglandins. It also indicates that addition of
NSAIDs to conventional anti-cancer therapies may enhance
their anti-tumor effect.References
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